Mohammed S Osman1, Jan Willem Cohen Tervaert2. 1. Division of Rheumatology, Department of Medicine, University of Alberta, Edmonton, AB, Canada. 2. Division of Rheumatology, Department of Medicine, University of Alberta, Edmonton, AB, Canada. cohenter@ualberta.ca.
Abstract
PURPOSE OF REVIEW: ANCA-associated vasculitides (AAV) are a group of rare diseases characterized by blood vessel inflammation and the presence of circulating anti-neutrophil cytoplasmic antibodies recognizing proteinase-3 (PR3) (PR3-ANCA) or myeloperoxidase (MPO), MPO-ANCA. RECENT FINDINGS: Historically, ANCAs have been used as biomarkers for disease associations and increases of ANCA levels as predictors of relapse in patients with AAV. In this review, we will summarize and highlight the most recent developments for using ANCA as predictive biomarkers and review some of the important disease-specific features in patients with AAV.
PURPOSE OF REVIEW: ANCA-associated vasculitides (AAV) are a group of rare diseases characterized by blood vessel inflammation and the presence of circulating anti-neutrophil cytoplasmic antibodies recognizing proteinase-3 (PR3) (PR3-ANCA) or myeloperoxidase (MPO), MPO-ANCA. RECENT FINDINGS: Historically, ANCAs have been used as biomarkers for disease associations and increases of ANCA levels as predictors of relapse in patients with AAV. In this review, we will summarize and highlight the most recent developments for using ANCA as predictive biomarkers and review some of the important disease-specific features in patients with AAV.
Authors: Eli M Miloslavsky; John L Niles; Zachary S Wallace; Frank B Cortazar; Ana Fernandes; Karen Laliberte; John H Stone Journal: Semin Arthritis Rheum Date: 2018-02-03 Impact factor: 5.532
Authors: M J Kemna; W Schlumberger; P van Paassen; C Dähnrich; J G M C Damoiseaux; J W Cohen Tervaert Journal: Clin Exp Immunol Date: 2016-05-23 Impact factor: 4.330
Authors: Michael J Kemna; Rosina Plomp; Pieter van Paassen; Carolien A M Koeleman; Bas C Jansen; Jan G M C Damoiseaux; Jan Willem Cohen Tervaert; Manfred Wuhrer Journal: EBioMedicine Date: 2017-01-28 Impact factor: 8.143